Humira carries AbbVie in its first quarter as standalone company

Eric Palmer AbbVie's rheumatoid arthritis drug Humira did exactly what the new company needed it to do in the first quarter. It returned significantly higher sales and ...

Industry Voices: Time to Take Fecal Transplantation Seriously

Alok Saboo By Bernat Olle, PureTech Ventures The NEJM‘s recent publication of the first randomized, controlled trial of fecal transplantation (FT) is a big deal for research ...

Pfizer appealing CHMP ruling on RA treatment Xeljanz

Eric Palmer Pfizer has big expectations for its oral rheumatoid arthritis treatment Xeljanz–about $ 3 billion worth. But those expectations were struck a serious blow when European ...

Ipsen warns of shortages of its orphan drug Increlex

Eric Palmer French drugmaker Ipsen says shortages of its orphan drug Increlex appear inevitable because of ongoing issues at a Lonza plant in the U.S. The drug is used to treat ...

Theravance to split into two companies

Ryan McBride Theravance ($ THRX) plans to break apart into two publicly traded companies. The South San Francisco-based biotech announced Thursday afternoon that the separation would ...

U.S. feds launch probe into AstraZeneca plant in U.K.

Eric Palmer U.S. federal investigators have taken an interest in manufacturing at an AstraZeneca ($ AZN) plant in England, but the company is remaining mum about what precisely they ...

New Bristol-Myers drug growth cushions plummeting Plavix sales

Tracy Staton Bristol-Myers Squibb ($ BMY) chose a good day to report its first-quarter results. AstraZeneca's ($ AZN) declining sales and profits help blunt its own disappointments: ...

Acumen Pharma reveals A round closing to fund Alzheimer’s drug research

Ryan McBride Driven to test another amyloid-beta mechanism in Alzheimer's, Acumen Pharmaceuticals has wrapped up the first closing of a planned $ 20 million Series A round from ...

Japan’s Eisai amps up in China with new manufacturing plant

Tracy Staton Eisai is drawing a bigger target on China with plans for a new manufacturing plant near Suzhou. The Japanese drugmaker will use the plant to tap growing demand in that ...

Eli Lilly slugs it out with J&J on Alzheimer’s drug patent claim

John Carroll With a new late-stage study being prepped for the Alzheimer's drug solanezumab, Eli Lilly found itself in a London courtroom this week defending itself against a patent ...

European regulators tag 100-plus drugs with ‘black triangle’

Tracy Staton The European Medicines Agency has rolled out its list of drugs that soon will bear the "black triangle." The labeling logo is designed to encourage doctors and ...

Bristol-Myers gains FDA’s ‘breakthrough’ track in race for hep C drug approval

John Carroll Bristol-Myers Squibb just gained an inside regulatory track in the frantic race to get new interferon-free hepatitis C drugs to the FDA. The big biotech reported in its ...
Page 4 of 17« First...23456...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS